Trial Profile
A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs PN 10943A (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors Protagonist Therapeutics
- 10 Mar 2020 According to a Protagonist Therapeutics media release, data from this trial were presented in an oral presentation at the 2019 Digestive Disease Week conference.
- 06 Nov 2019 According to a Protagonist Therapeutics media release, results were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
- 01 Aug 2019 According to a Protagonist Therapeutics media release, complete data from the trial will be presented at the American College of Gastroenterology Conference in October 2019.